Later in life, I closely followed the various studies at Johns Hopkins, UCLA, and NYU and felt it would be an honor to be part of psychedelic history and help humankind. In August of 2015, I was accepted as a participant in the Phase I Psilocybin Pharmacokinetics Study, an FDA-approved clinical trial at the University of Wisconsin to determine the pharmacokinetics of psilocybin in support of Phase II and Phase III trials for people with incurable cancer.
After an application process and acceptance, I met my guides Dan and Karen through a series of four two-hour sessions. The meetings with my guides flowed smoothly. Sharing my story was mixed in with their own sharing from their lives.
This helped cement a bond of trust that would serve me greatly as I progressed down into the pits of hell, which I had no idea I would soon be hitting.
I was also scheduled for three “dose days” when I would be administered psilocybin—including the highest dose in this study.